Blood pressure reduction and ACE inhibition in secondary stroke prevention: Mechanism uncertain

Stroke

Volumn 34, Issue 5, 2003, Pages 1335-1336

  Davis, Stephen M ^a,b   Donnan, Geoffrey A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Angiotensin converting enzyme inhibitors; Blood pressure; Stroke prevention

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL; RAMIPRIL;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; SHORT SURVEY; STROKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037967036     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000069265.51001.D8     Document Type: Short Survey

References (5)

1. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein K, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;355:1534-1535.
2. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342: 145-153.
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 patients with previous stroke or transient ischaemic attack. Lancet. 2001;358: 1033-1041.
4. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
5. The ALLHAT Officers, and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.